Also, additional CRISPR/Cas9 studies by the Dittmer group showed that PEL cells could circumvent IRAK1 and IRAK4 loss, calling into question the potential of IRAK1/4 inhibition by itself as a treatment for PEL. The gene discussed is IRAK1; the disease is primary effusion lymphoma.